Healthcare marketing UK: what stays the same, what changes
A reasonable amount of healthcare marketing looks like ordinary B2B marketing. The buyer is a person with a job to do, who wants proof over adjectives.
What changes is the cost of being wrong and the number of people who have to agree. A regulatory layer sits on top of every claim, which is why healthcare marketing feels harder than it often is, and why the leaders who run it well do fewer campaigns to a higher standard rather than more campaigns at a lower one.
Compliance shapes healthcare marketing. The buyer journey is still a buyer journey.
A clinician researching a new diagnostic still reads case studies. A trust digital director still searches Google before a procurement window opens. A pharma medical-affairs lead still scans LinkedIn for whoever published the most credible piece on the indication this quarter. The pattern of awareness, consideration and decision is intact.
The rules change what you can put inside that pattern. The governing principle is straightforward: you cannot promote what the product has not been cleared to claim, and you cannot promote prescription-only medicines to the public. In practice that means a medical device cannot be advertised against an indication it has not been cleared for, and a prescription-only medicine cannot be promoted to the public under any circumstance. A digital health product claiming DTAC alignment before its DTAC submission has been completed is a different version of the same mistake. Teams that treat the rules as a late-stage constraint struggle; teams that build the rules into the brief scale.
Where healthcare marketing actually breaks
Healthcare marketing rarely breaks at the MHRA stage. It breaks at the internal medical-affairs review stage, two weeks before the campaign was due to go live, when the regulatory team flags a phrase that could imply an off-label benefit or a clinical-evidence claim the data does not yet support. By the time a campaign reaches the regulator, the company has usually already self-corrected.
I have sat in three pharma compliance review meetings in the last twelve months where a campaign died at internal sign-off, not external scrutiny. In each case, marketing had briefed the agency on MHRA rules and assumed that was the bar. The bar inside the company was tighter, and closer to the medical-affairs reading of the published evidence than to the regulator's interpretation of the Code. That is the breakage point.
The second common breakage is in NHS-targeted campaigns where the marketing team treats the NHS as a single buyer. There is no single NHS buyer. There are around 36 Integrated Care Boards (ICBs) commissioning at system level as of April 2026, reduced from 42 following the Phase 1 ICB merger programme that took effect on 1 April 2026. Around 210 NHS trusts run their own procurement underneath that commissioning architecture. Digital-transformation programme leadership sits at national and regional level, and clinical champions operate inside individual services. A campaign written to a generic NHS buyer converts none of them.
The UK regulations every healthcare marketer needs to know
You do not need to be a regulatory specialist to run healthcare marketing well. You do need a working map of which framework applies to which claim, where the source documents live, and who inside your business owns the relationship with each regulator.
MHRA rules for medical devices and pharmaceuticals
The Medicines and Healthcare products Regulatory Agency is the UK regulator of medicines, medical devices and blood components. Its remit covers what you can claim about a product, who you can promote it to, and how those claims are substantiated.
Two things catch healthtech and medtech marketers out most often. The first is software classification, where a digital product that implies diagnosis, treatment decision support or clinical advice can be classified as a medical device regardless of any "for informational purposes only" disclaimer. The second is post-launch claims, which the 2024 PMS regulations tightened further. As of 16 June 2025, a new UK framework for medical-device post-market surveillance came into force under The Medical Devices (Post-market Surveillance Requirements) (Amendment) Regulations 2024. Manufacturers now have a tighter ongoing reporting obligation, which affects what claims can be made in medical device marketing as the data evolves.
Prescription-only medicines cannot be advertised to the public. Over-the-counter products sit under a more permissive but actively-enforced regime. The MHRA Advertising Standards team enforces both, against the rules in the MHRA Blue Guide. If you are writing about MHRA marketing rules, cite the source document and name the year, and start at the MHRA homepage on gov.uk.
The ABPI Code in plain English
The ABPI Code of Practice governs the promotion of prescription medicines to healthcare professionals and other relevant decision-makers in the UK. The current edition is the 2024 Code, effective from 1 October 2024 with full enforcement from 1 January 2025. It is administered by the Prescription Medicines Code of Practice Authority (PMCPA).
The Code explicitly applies to digital channels and social media. ABPI code marketing rules do not stop at the boundary of paid display, and a LinkedIn post by a pharma employee promoting a prescription medicine to clinicians is in scope. The 2024 update changed how prescribing information is provided, including digital access mechanisms such as QR codes, under Clause 12. An abridged complaints procedure introduced in 2024 has reduced the time and cost of resolving lower-tier complaints.
The pharma marketing UK community treats the Code as the operating system, not the regulator. PMCPA rulings shape practice as much as the Code text itself. A specialist healthcare marketing agency UK working in pharma should be reading PMCPA case rulings monthly.
GDPR and UK GDPR for patient and clinician data
Health data is special category data under Article 9 of the UK GDPR. Any processing requires both a lawful basis under Article 6 and a separate condition under Article 9. The ICO sets this out in its special category data guidance.
For marketing, this matters in two scenarios. If you are running campaigns aimed at patients directly, explicit consent is usually the cleanest route, with PECR (the Privacy and Electronic Communications Regulations) sitting on top for electronic marketing. If you are using health data for research or secondary use, the ICO and the Health Research Authority specifically recommend not relying on consent as the lawful basis where public-task or other Article 6 grounds apply. Clinician marketing lists built from publicly available professional registers are lower-risk, but the standard UK GDPR principles around lawful basis, data minimisation and transparency still apply.
DTAC, DCB0129 and DCB0160 for digital health products
DTAC, the Digital Technology Assessment Criteria, is NHS England's framework for assessing digital health technologies. The current version is DTAC Form 2.0, released February 2026 and published at transform.england.nhs.uk. It covers five core areas: clinical safety, data protection, technical security, interoperability, and usability and accessibility. DTAC applies to any digital health technology assessed by an NHS or social care organisation in England, regardless of procurement route. The 2024 review reduced the question count by approximately a quarter, removed duplication with the Data Security and Protection Toolkit, and aligned scope with NICE.
For marketers, the five pillars also read as a positioning framework. A healthtech that shows DTAC alignment on its website, in sales decks and in case studies shortens NHS evaluation time, which is why DTAC belongs in the marketing brief, not just the compliance back-office.
DCB0129 and DCB0160 are the clinical risk management standards underneath. DCB0129 governs manufacturers of health IT systems. DCB0160 governs deploying organisations such as NHS trusts. Both are mandatory under the Health and Social Care Act 2012, and both require a nominated Clinical Safety Officer who is a senior clinician registered with the GMC, NMC or equivalent body. The standards sit on the NHS Digital information standards site.
A practical caveat: this DCB detail is correct as of April 2026, with both standards currently under NHS England review. A v2 may land during 2026 to 2027.
NHS Digital procurement gates and what they mean for marketing claims
NHS procurement is its own architecture. The financial framework for the year is set by NHS England's 2025 to 2026 financial directions. The Autumn Budget 2025 added approximately £300 million of new capital for NHS technology. NHS trust IT spend reached £4.1 billion in 2025, up 9% year on year, per the NHS IT Leadership Survey reported in February 2026.
The procurement reality that matters most for campaign design is alignment. Marketing claims need to align with the framework you are listed against, and a G-Cloud 14 listing description should not be contradicted by your website. ICBs commission at system level and trusts procure at organisation level, so the same product is sold differently to each. Procurement windows align with financial-year cycles, which means awareness work in Q1 and Q2 often outperforms direct response in Q4 when budgets are spoken for.
When a regulatory question is genuinely ambiguous, the answer is rarely on a forum. It is in the source document, a PMCPA case ruling, an ICO decision notice, an MHRA classification opinion, or a direct query to the relevant body. For the strategic ambiguity (something permissible but inadvisable, compliant on paper but commercially counter-productive), you need a healthcare marketing UK partner built for regulated work.
Free 30-minute compliance audit of your current healthcare marketing. We will review your live materials against MHRA, ABPI, ICO and DTAC requirements and tell you where the risk sits before your next sign-off cycle. Book a free audit.
Who you are actually selling to
Select your buyer type to see the most relevant tactics
The most common mistake in NHS marketing is treating the NHS as one buyer, and the second is conflating clinician influence with clinician buying authority. The buyer is more granular than the org chart suggests.
NHS trusts, ICBs and the procurement-led buyer
There are approximately 36 ICBs in England as of April 2026, following the Phase 1 merger programme that took effect on 1 April 2026 (down from the 42 established in July 2022 to replace the Clinical Commissioning Group system). Each one covers a defined geography and brings together the trusts, primary care networks and community providers in that footprint. Around 210 NHS trusts then sit underneath that commissioning architecture and run their own internal procurement against contracts the ICB has helped shape.
For a healthtech selling into the NHS, the marketing motion changes by buyer type. ICB-level work is strategic, slow, and rewards content that frames the system-level case for change. Trust-level work is operational, faster, and rewards proof of deployment, security and integration with existing infrastructure. NHS trust IT spend at £4.1 billion in 2025 is not a single addressable market either: it splits across acute, mental health, community and ambulance trusts, with very different procurement priorities in each.
Private healthcare providers and the operator-led buyer
The private healthcare buyer behaves more like a standard B2B operator. Decisions concentrate around a smaller group, often the chief operating officer, the head of digital, the chief medical officer and the finance director. Procurement cycles are shorter and capital availability is higher per head than in NHS trusts.
The trade-off is competitive intensity. Private providers are evaluated against tighter operational metrics, so the bar for proof of clinical and operational outcomes is high. Marketing into this audience leans toward case studies with named provider outcomes, ROI modelling and integration evidence. Generic capability content rarely lands.
Pharma commercial teams versus medical affairs
In pharma, two functions touch marketing: commercial (brand, market access, sales) and medical affairs (medical science liaison, scientific communications, evidence generation). Commercial wants reach, brand presence and prescriber preference. Medical affairs wants scientific accuracy, balanced presentation and adherence to the Code. The most common mistake in pharma marketing UK programmes is treating commercial and medical affairs as one customer; a healthcare marketing UK programme aimed at pharma needs to be designed with both functions in mind from the brief, not at sign-off.
Clinicians as buyers versus clinicians as influencers
Clinician influence is not clinician buying. The clinician who recommends a tool to procurement is rarely the clinician who signs the contract. Programmes that optimise heavily for clinician awareness while ignoring procurement convert at low rates because procurement treats clinical enthusiasm as one input, not the deciding factor. The right approach pairs clinician-facing content (clinical credibility, peer endorsement, specialty thought leadership) with procurement-facing content (security, integration, total cost of ownership, contract terms, deployment timelines).
Budget cycles, procurement windows and the marketing implications
The NHS financial year runs April to March. Trust budgets are usually committed by the end of Q3, with limited flexibility in Q4 unless capital is available. ICB commissioning runs to a longer horizon. Pharma cycles are calendar year, with promotional planning typically locked at the previous year's Q3 to Q4. The implication: the strongest campaigns front-load awareness and demand-generation in Q1 and Q2, build evaluation content through Q3, and reserve Q4 for sales-enablement. Running a launch campaign in February against an NHS trust that has already committed its budget is an expensive way to learn this.
Channels that work in healthcare marketing
Channel selection follows the same principle anywhere. Match the channel to the buyer, the message and the proof you have. The channels below carry the most weight in UK healthcare, in the order I would prioritise for a Series A to C healthtech with limited budget and the obligation to show pipeline.
Content marketing for clinical and procurement audiences
Long-form content is the foundation of healthcare marketing because the audiences read. Clinicians read journals, guidelines and peer commentary. Procurement teams read framework descriptions, case studies and security documentation. Both groups credit specificity. The agencies and in-house teams that win in this segment have built B2B content marketing capability tuned to clinical evidence framing and procurement-relevant detail, not generic top-of-funnel SaaS content. What works: technical white papers tied to a real clinical or operational problem, framework explainers (DTAC, DCB, ABPI) for the relevant decision maker, named case studies with verifiable outcomes, FAQ-style content that answers the questions buyers ask in evaluation.
SEO for healthcare: winning clinical and procurement queries
Healthcare SEO is harder than most B2B SEO because the search intent is concentrated and Google applies elevated trust criteria to your-money-or-your-life topics, particularly anything patient-facing. The compliant healthcare marketing playbook for SEO leans on demonstrable expertise, named authors with credentials, citation of primary sources, and clear authoring and editorial provenance. For healthtech selling B2B, the highest-value queries are usually procurement and framework adjacent: framework explainers, integration content, role-specific guides for digital directors and ICB technology leads. Forge runs specialist SEO services for healthcare clients on this basis.
LinkedIn for clinical leaders and trust-level decision-makers
LinkedIn is where most NHS digital directors, ICB commissioning leads and pharma commercial heads spend the largest share of their professional discovery time. Long-form posts from named authors with operational detail consistently outperform branded company posts. The most valuable LinkedIn motion is to build a small set of credible voices inside your business, give them a publishing rhythm, and treat company-page activity as a backstop. Paid LinkedIn delivers in two scenarios: account-based targeting at named NHS trusts, ICBs or pharma companies, and lead-gen forms for clinical or procurement roles when the asset is genuinely useful. Broader audience targeting is rarely cost-effective in this market.
Healthcare events and clinical conferences
UK events worth budget include HETT, Rewired, the BMJ events programme, the ABHI Innovation Day series, ABPI events and the major royal college conferences. Each pulls a specific subset of the audience. Sponsorship is often the wrong default. The higher-return move is usually to get a named voice from the business onto a panel, into a workshop or on a podium with original research. A platform slot with a credible insight reaches the room and produces evergreen content; a sponsored stand without a hook buys foot traffic and little else.
PR with UK healthcare media
The UK healthcare press is small and recognisable. Digital Health, HSJ, Pharmafield, Pharmaceutical Journal, BMJ and Med-Tech Innovation News all have specific editorial preferences and small editorial teams. PR motion for healthtech is most effective when it pairs original data, named clinical opinion and a story arc that maps to the publication's interests. Press releases without data rarely run.
ABM for hospital, pharma and digital health sales
Account-based marketing is the right primary motion for high-value healthcare deals because the addressable market per segment is small. There are around 210 trusts. There are approximately 36 ICBs. The major UK pharma list runs to about 30 accounts of meaningful size. For high-ACV healthtech, structured ABM programmes typically outperform broader demand-generation work. A practical ABM stack for NHS-targeted healthtech: enriched named-account list at trust and ICB level, tiered targeting by buying group (digital director, CIO, head of innovation, clinical lead), tailored content per account or account cluster, paid social and email orchestration on top, and a sales motion ready to take warm signals straight to outreach.
Want a second pair of eyes on your healthcare marketing? Book a free audit and we will review your current programme against MHRA, ABPI, ICO and DTAC.
What the work looks like in practice
Two named examples from current Forge Together work, both live on our case-studies page, one at the B2B procurement-led end and one at the patient-facing editorial end.
Credentially: scaling a healthcare credentialing platform
Credentially is a healthcare credentialing software platform serving NHS, private and US healthcare buyers. The brief was to expand market presence and acquire customers in a competitive B2B healthcare environment, where the addressable buyer (heads of HR, talent acquisition, clinical operations) is sophisticated, time-poor and procurement-led.
Forge built the growth marketing strategy from positioning through to channel mix. The work covered an overhaul of organic social, a cornerstone white paper that re-anchored the category framing, a scalable lead-generation engine and the call-to-action architecture to convert traffic into qualified pipeline. The published outcomes are 3x monthly organic web traffic, a 150% increase in web users from social, and a scalable lead generation engine driving consistent customer acquisition. You can see the full Credentially case study on our site.
This case fits a healthcare pillar rather than a generic SaaS one because of the buyer architecture. Credentialing touches clinical safety, NHS Employment Check Standards and the wider compliance stack, and the marketing has to speak to readers evaluating you for both operational fit and clinical risk reduction. Healthcare-literate positioning lands. Generic SaaS positioning falls flat.
Salve: building authority in fertility content
Salve is a fertility business that needed to establish category authority in IVF content and refresh its brand identity. The audience is patient-facing, the content sits firmly in your-money-or-your-life territory, and the bar for evidence and editorial standards is high. People making decisions about IVF read carefully and compare sources.
Forge delivered a complete brand refresh and visual identity redesign, a content marketing strategy, an in-depth IVF guide as the lead magnet, and an SEO-optimised content architecture built for clinical authority. The outcomes are a 60% increase in US organic traffic, 100% monthly organic traffic growth, and a 268% monthly social engagement increase. Salve is now recognised as a reference resource for IVF information across multiple search markets. The full Salve case study is on our case-studies page.
This case sits alongside Credentially because it evidences the other end of the healthcare marketing range. Where Credentially is B2B procurement-led growth, Salve is patient-facing category authority.
Common mistakes healthcare marketers make
Compliance treated as a creative ceiling
The most expensive mistake is treating compliance as a ceiling on what the marketing team can do, instead of a credibility floor it builds on. Briefs that say "make it compliant" produce content that survives review and changes nobody's mind. Briefs that say "make this clinically credible and procurement-relevant within the rules" produce content that survives review and lands. The fix is to involve regulatory and medical-affairs in the brief, not the sign-off.
Marketing to clinicians like standard B2B buyers
Clinician audiences read differently. They give weight to peer endorsement and original evidence in a way that procurement audiences do not. They are more sceptical of marketing language and quicker to disengage from generic content. Treating them like generic SaaS buyers produces content that performs poorly on the metrics that matter. Clinician content needs named clinical authors, evidence-led framing and a willingness to discuss limitations as well as benefits.
Procurement cycles
NHS procurement runs slower than most marketing leaders plan for. Six months is short. Twelve months is normal. Programmes that expect to land pipeline within a quarter build expectations they cannot meet, which erodes board confidence in marketing's contribution to revenue. The fix is a dashboard that distinguishes early-stage activity (engaged accounts, content saves, demo requests) from late-stage activity (procurement engagement, security review, contract negotiation), and a board narrative that gives marketing credit for the early-stage motion months before revenue lands.
Are you really selling something specific?
A "5 trends in healthcare 2026" article does nothing for any reader in this market. It is not specific enough to help a digital director, an ICB commissioner, a medical affairs lead or a procurement officer. The work that converts is specific to the regulatory framework, the buyer type, the deployment context and the evidence base. If your editorial calendar is full of generic round-ups, the underlying problem is usually a research-thin briefing process.
Hiring without sector experience
Healthcare marketing requires sector literacy. An agency that does not know the difference between DCB0129 and DCB0160, has not read a recent PMCPA ruling, and cannot explain how an ICB commissions versus how a trust procures will produce work that needs heavy correction at every stage. The cost of that correction usually exceeds the cost difference between a generalist and a specialist healthcare marketing agency UK. The minimum bar to ask of any healthcare marketing partner is named regulatory familiarity, named NHS or pharma client work, and a process for keeping up to date with the regulators.
How to choose a healthcare marketing partner
Choosing a partner for healthcare marketing is a higher-stakes decision than for most other B2B sectors. The cost of a poor choice is not just bad creative. It is rejected campaigns, missed procurement windows, regulatory exposure and, in the worst case, damaged relationships with clinical buyers who do not give third chances.
Five questions that filter most agencies out fast
The five questions below will, in my experience, separate a genuinely capable healthcare marketing partner from a generalist agency claiming sector experience.
- Name the last three PMCPA rulings that shaped your pharma work. If they cannot, they are not reading the rulings.
- Walk me through a campaign of yours that failed compliance review and what you changed. If the answer is vague, they have not been through the cycle.
- Describe how you treat a marketing claim that sits in DTAC scope. If the answer is "we check it against DTAC", they have not built the workflow.
- Tell me how your team stays current on MHRA marketing rules. If they dodge it, you have your answer.
- Name two healthcare clients you have published work with. If they cannot, they do not have referenceable case work.
These can be asked in 15 minutes and will save weeks of misalignment.
In-house, agency or hybrid
The right structure depends on the volume and rhythm of your marketing. A pharma business with sustained brand work across multiple indications usually needs in-house marketing leadership with agency support for execution. A Series A healthtech with a single product and limited bandwidth often gets more from a focused agency partner than from an in-house hire. A scaling healthtech in the Series B to C range tends toward a hybrid: an in-house marketing director with strategic ownership, supported by an agency that brings sector-specific execution capacity. Cost varies widely and depends on scope, seniority, channel mix and content volume. The honest framing is that the cheapest option is rarely the most cost-effective once rework, missed cycles and compliance risk are priced in.
Red flags in agency pitches for healthcare work
Treat the following as warning signs in an agency pitch. Use of words like "patient-centric" or "data-driven" without specific evidence behind them. Inability to name regulators by document reference rather than acronym. Healthcare client logos in the deck without a referenceable case study. Pitches built around channels (we do paid social, we do SEO) rather than around buyer architecture. Unwillingness to commit to a process for compliance briefing at the start of work. If two or more of these appear, the agency is unlikely to scale healthcare work well. A good healthcare marketing agency UK team will pre-empt these in the pitch itself.
FAQ
Where to take this next
The two practical next steps for a marketing leader reading this guide are usually the same. Audit what is currently live against the regulatory framework that applies to it. Map the buyer architecture you are trying to reach against the channels you are actually running. Most healthcare marketing improvement comes from those two audits, not from new tactics.
If you want a second pair of eyes on either of those, that is what we do. Forge Together's healthcare marketing service runs both audits as the entry point to most engagements, and we will tell you straight if your existing setup is in good shape and you do not need outside support. Healthcare marketing UK programmes that are working should not be disrupted, and we say so when we see them.
To talk through your programme, book a healthcare marketing strategy call with Luke. One conversation, and a clear read on where the strongest moves sit in your next two quarters.